Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML

NCT00373373 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

200

Enrollment

OTHER

Sponsor class

Conditions

Acute Myeloid Leukemia

Interventions

DRUG: Sorafenib
DRUG: Placebo

Sponsor

University Hospital Muenster

Collaborators

[object Object]